Fresenius Medical Care AG (NYSE:FMS) Shares Sold by Eagle Asset Management Inc.

Eagle Asset Management Inc. lowered its holdings in shares of Fresenius Medical Care AG (NYSE:FMSFree Report) by 3.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,861 shares of the company’s stock after selling 551 shares during the period. Eagle Asset Management Inc.’s holdings in Fresenius Medical Care were worth $310,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in FMS. Pacer Advisors Inc. raised its position in Fresenius Medical Care by 14,252.1% during the fourth quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock worth $10,173,000 after acquiring an additional 484,998 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Fresenius Medical Care by 362.2% during the third quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock worth $5,580,000 after acquiring an additional 202,991 shares during the last quarter. Moran Wealth Management LLC acquired a new position in Fresenius Medical Care during the fourth quarter worth about $3,247,000. Partnership Wealth Management LLC acquired a new position in Fresenius Medical Care during the fourth quarter worth about $2,340,000. Finally, O Shaughnessy Asset Management LLC raised its position in Fresenius Medical Care by 259.5% during the third quarter. O Shaughnessy Asset Management LLC now owns 92,635 shares of the company’s stock worth $1,995,000 after acquiring an additional 66,864 shares during the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on FMS shares. Truist Financial lifted their price target on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a report on Wednesday, May 15th. StockNews.com started coverage on shares of Fresenius Medical Care in a report on Saturday, June 1st. They set a “strong-buy” rating for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $32.25.

View Our Latest Stock Report on Fresenius Medical Care

Fresenius Medical Care Price Performance

Fresenius Medical Care stock opened at $21.22 on Thursday. Fresenius Medical Care AG has a 1 year low of $16.37 and a 1 year high of $27.72. The firm has a 50 day moving average price of $20.44 and a 200 day moving average price of $20.21. The company has a market cap of $12.45 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 1.13 and a beta of 0.93. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.14 and a current ratio of 1.50.

Fresenius Medical Care (NYSE:FMSGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.10. Fresenius Medical Care had a net margin of 2.48% and a return on equity of 5.29%. The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.15 billion. Sell-side analysts predict that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Fresenius Medical Care Cuts Dividend

The business also recently announced an annual dividend, which was paid on Monday, June 3rd. Investors of record on Monday, May 20th were issued a $0.437 dividend. The ex-dividend date was Friday, May 17th. This represents a yield of 2.35%. Fresenius Medical Care’s payout ratio is 49.44%.

About Fresenius Medical Care

(Free Report)

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Stories

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG (NYSE:FMSFree Report).

Institutional Ownership by Quarter for Fresenius Medical Care (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.